ASH Meeting on Lymphoma Biology

ASH Meeting on Lymphoma Biology

Highlights and interviews from the American Society of Hematology’s Meeting on Lymphoma Biology

R-EPOCH May Be Viable Option for Patients with High-Risk DLBCL

Results from a single-center study show that the drug combination R-EPOCH leads to a high overall response rate (ORR) in patients with high-risk diffuse...

Ibrutinib Shows Survival Benefit in Previously Treated CLL/SLL Patients with High-Risk Disease

Longer-term data from the phase III RESONATE trial – a head-to-head comparison of ibrutinib and ofatumumab – continue to demonstrate ibrutinib’s efficacy in patients...

Tazemetostat for Patients with Pretreated Non-Hodgkin Lymphoma

Preliminary data from an ongoing, global, phase II trial of tazemetostat, a first-in-class EZH2 inhibitor, in patients with relapsed or refractory non-Hodgkin lymphoma (NHL)...

Mechanisms of Ibrutinib Resistance Varied in ABC DLBCL

Lymphoma cells may develop resistance to the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib using a variety of potentially druggable pathways, opening the door to...

Early Data Show EZH2 Inhibitor Active in Non-Hodgkin Lymphoma

The EZH2 inhibitor EPZ-6438 appears to be a well-tolerated drug and is showing early evidence of anti-lymphoma activity in patients with non-Hodgkin lymphoma of...

Potent Small-Molecule BCL6 Inhibitor Active against ABC-, GCB-DLBCL Cells

Researchers have identified a novel, potent, and specific BCL6 inhibitor that effectively inhibited tumor growth in vitro and in vivo in activated B-cell (ABC)...

ASH Meeting on Lymphoma Biology: Creating a Roadmap for Future Research

More than 350 lymphoma experts from around the world convened at the American Society of Hematology’s first Meeting on Lymphoma Biology to share cutting-edge...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.